Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2345${count})

  • Defining Cognitive Phenotypes of Parkinson’s Disease, 2011
    Bioanatomical Phenotype of Parkinson's Disease With and Without Cognitive Impairment

    Objective/Rationale:             
    Mild cognitive impairment (MCI) and dementia are common in Parkinson’s disease. However, presently, it is difficult to recognize which aspects of cognitive changes are...

  • Improving Levodopa Delivery, 2011
    Continuous Subcutaneous Levodopa Prodrug Infusion

    Objective/Rationale:
    Numerous studies demonstrate that continuous levodopa infusion can result in reductions of more than 50 percent in time spent in the "off" state and time spent with severe...

  • Target Validation, 2011
    Caspase-8 Control Microglia Activation and Neurotoxicity in Parkinson's Disease

    Objective/Rationale:
    Sustained microglia activation and resulting neuroinflammation is believed to play an important role in the mechanism of chronic dopaminergic neuronal loss in Parkinson’s disease...

  • MJFF Research Grant, 2011
    Development of Highly Sensitive and Specific Antibodies Against Oxidized DJ-1 as a Biomarker for Parkinson's Disease

    Objective/Rationale:
    Mutations in the DJ-1 gene are associated with an early-onset familial form of PD and DJ-1 protein has been shown to be lower in the CSF of sporadic PD compared to controls. DJ-1...

  • Defining Cognitive Phenotypes of Parkinson’s Disease, 2011
    Neurochemical Correlates of Cognitive Phenotypes in PD

    Objective/Rationale:
    Parkinson’s disease causes neurodegeneration in multiple subcortical nuclei, including substantia nigra, locus coeruleus, dorsal raphe nucleus, and nucleus basalis. Each of these...

  • Target Validation, 2011
    TGF-beta Signaling as Novel Therapeutic Treatment for Parkinson's Disease

    Objective/Rationale:
    Finding ways to protect dopaminergic neurons from degeneration could provide new therapies for Parkinson’s disease (PD). Transforming growth factor betas (TGF-betas) are essential...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.